Nonalcoholic Steatohepatitis (NASH) Market by Therapeutics | 2020
NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017.
NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (<strong>NASH</strong>) <strong>Market</strong><br />
Opportunity Analysis and Industry Forecast, 2016-2023<br />
Global<br />
Opportunity<br />
Analysis and<br />
Industry Forecast,<br />
2017-2023
Introductionof<br />
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (<strong>NASH</strong>) <strong>Market</strong><br />
The global market is expected to garner $1.6 billion <strong>by</strong> <strong>2020</strong>, registering a CAGR of<br />
25.6% during the period 2014-<strong>2020</strong>. The high prevalence of Type II diabetes and<br />
obesity, which lead to <strong>NASH</strong> and other nonalcoholic fatty liver diseases (NAFLD), would<br />
boost market growth. North America's heightened focus of <strong>NASH</strong> research has<br />
resulted in its accounting for nearly half of the global market. It is also the region with<br />
the maximum occurrences of <strong>NASH</strong> and other nonalcoholic fatty liver diseases. Europe<br />
ranks second in terms of the prevalence of <strong>NASH</strong>.<br />
The number of patients living with the diabetes worldwide is expected to soar from<br />
371 million in 2012 to 552 million <strong>by</strong> 2030. This suggests that <strong>by</strong> 2030, there will be 3<br />
new cases of diabetes every 10 seconds. "The rampant growth of diabetes and obesity<br />
has prompted pharmaceutical manufacturers to seek out novel pharmaceutical<br />
solutions to tap promising potential in <strong>NASH</strong>," states AMR analyst Roshan Deshmukh.<br />
"Instrumental initiatives and increasing clinical trials for the development of novel<br />
<strong>NASH</strong> therapeutics will steer its faster commercialization," adds the analyst.
Introductionof<br />
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (<strong>NASH</strong>) <strong>Market</strong><br />
Scope of the Report<br />
Key Benefits<br />
Key Audiences
Key Benefits<br />
1. Various opportunities for non alcoholic fatty liver disease therapeutics present in<br />
developed as well as developing economies are thoroughly assessed.<br />
2. Substitute treatments and their potential impact on <strong>NASH</strong> therapeutics are strategically<br />
quantified in the report.<br />
3. Opportunities from a business perspective latent in the Asia-Pacific region are brought to<br />
light.<br />
4. <strong>Market</strong> dimensions of diagnostic techniques used in <strong>NASH</strong> monitoring provide a clear<br />
outline of the <strong>NASH</strong> therapeutics research market<br />
5. Geography-wise segmentation of clinical trials is conducted to provide strategic<br />
intelligence to the stakeholder.<br />
6. Drivers and factors limiting market expansion are studied in detail.<br />
Click to Access Full Summary of Non-alcoholic <strong>Steatohepatitis</strong> <strong>Market</strong>
Table of Content (TOC)<br />
Chapter 1: Introduction<br />
Chapter 2: Executive Summary<br />
Chapter 3: <strong>Market</strong> Overview<br />
Chapter 4: <strong>Market</strong> Beyond: What To Expect By 2025<br />
Chapter 5: Global <strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> <strong>Market</strong> By Drug Types<br />
Chapter 6: Global <strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> <strong>Market</strong> (Pipeline Drug Analysis)<strong>by</strong><br />
Geography, 2013-<strong>2020</strong><br />
Chapter 8. Company Profiles
Segments<br />
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (<strong>NASH</strong>) <strong>Market</strong>
Segments<br />
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (<strong>NASH</strong>) <strong>Market</strong><br />
GFT505<br />
Placebo<br />
Obeticholic<br />
Acid (INT-<br />
747)<br />
<strong>Therapeutics</strong><br />
Pioglitazo<br />
ne<br />
Simtuzumab<br />
and<br />
Liraglutide<br />
(Victoza)<br />
Vitamin E
Company Profiles<br />
Ceramic Matrix Composites <strong>Market</strong><br />
1. Genfit<br />
2. Gilead Science<br />
3. Novo Nordisk<br />
4. Intercepts Pharmaceuticals<br />
5. Enzo Biochem, Inc.<br />
6. Raptor Pharmaceutical Corp.
Thank You<br />
Ceramic Matrix Composites <strong>Market</strong><br />
ThankYou!<br />
For More Details<br />
Do Enquiry<br />
https://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-<strong>NASH</strong>-market<br />
Follow Us On
Change language